米国におけるアルツハイマー病の治療のための輸液容量の予測
Jiahe Chen1, Beatrice Lin1, Evans Seow1
1The USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, USA.
Journal of Alzheimer's disease : JAD
|August 29, 2025
まとめ
アルツハイマー病 (AD) 治療へのアクセスを阻害する可能性があります. 数百万人の患者の治療が遅れる可能性がある.
科学分野:
- 神経科学
- 医療サービス研究
- 薬理学について
背景:
- 静脈内アルツハイマー病 (AD) 治療は,専門家の可用性とPETスキャン能力を超えた潜在的なアクセス障壁に直面しています.
- 輸液容量はAD治療の重要な要素ですが,しばしば見過ごされています.
研究 の 目的:
- 静脈内抗アルツハイマー病の治療を 提供する米国の能力を 推定する.
- 2024年から2033年までの予測需要と推定注入能力を比較する.
主な方法:
- 公開されたデータと,様々な環境 (医師の診療所,病院,独立センター,家庭内ケア) での注射場所の調査を利用した.
- 10年 (2024年-2033年) の間におけるAD治療に対する注射容量と需要の予測
主要な成果:
- 静脈内アルツハイマー病の治療能力は,2024年の37万回から2033年までに500万回に増加すると予測されています.
- 2033年までに1300万回以上の注射量の大幅な不足が予想され,推定220万人の患者に影響を与える.
- この不足はADの重要な治療へのアクセスが遅れる重大なリスクを示しています.
結論:
- 不十分な輸液容量は,新しい静脈注射抗アルツハイマー病の治療への患者のアクセスに重大な脅威をもたらします.
- アルツハイマー病患者の予防可能な障害の進行を緩和するために,注射容量の緊急拡張が必要である.
- AD治療のための代替投与経路は,長期的なアクセスソリューションにとって不可欠です.
関連する概念動画
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
One-Compartment Model: IV Infusion
280
Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
280
Compartment Models: Single-Compartment Model
2.4K
The single-compartment model serves as a simplified representation of the human body. This model assumes that the body functions as a single, well-mixed open compartment. When a drug is administered intravenously, it enters the body and quickly distributes uniformly. The drug then undergoes biotransformation and elimination, ultimately leaving the body. The volume of this compartment is referred to as the apparent volume of distribution into which the drug can uniformly distribute. In this...
2.4K
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Two-Compartment Open Model: IV Infusion
331
A two-compartment model is a vital tool in pharmacokinetics, providing an essential understanding of drug behavior, especially for those administered via zero-order intravenous infusion. This model outlines two compartments: the central compartment, where elimination occurs, and the peripheral compartment.
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
331


